Immunotherapy in Non-Small Cell Lung Cancer: Shifting Prognostic Paradigms

被引：13
|
作者：
Barnet, Megan B. [1 ,2 ,3 ]
Cooper, Wendy A. [3 ,4 ,5 ]
Boyer, Michael J. [3 ,6 ]
Kao, Steven [3 ,6 ]
机构：
[1] Garvan Inst Med Res, Darlinghurst, NSW 2010, Australia
[2] Univ New South Wales, Grad Res Sch, Sydney, NSW 2052, Australia
[3] Univ Sydney, Sydney Med Sch, Camperdown, NSW 2006, Australia
[4] Royal Prince Alfred Hosp, Camperdown, NSW 2006, Australia
[5] Western Sydney Univ, Sch Med, Penrith, NSW 2751, Australia
[6] Chris OBrien Lifehouse, Camperdown, NSW 2006, Australia
来源：
JOURNAL OF CLINICAL MEDICINE | 2018年 / 7卷 / 06期
关键词：
non-small cell lung cancer; immunotherapy; checkpoint inhibitors; MAINTENANCE THERAPY; OPEN-LABEL; NIVOLUMAB; DOCETAXEL; CHEMOTHERAPY; MULTICENTER; IPILIMUMAB; ANTIBODY; NECROSIS; PLACEBO;
D O I：
10.3390/jcm7060151
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Immune checkpoint inhibitors have shown efficacy in the treatment of non-small cell lung cancer (NSCLC) in the adjuvant, first- and subsequent-line settings. In metastatic disease, they provide hope of durable response where best-case scenario has long been inadequate. This progress has highlighted the immunogenic nature of NSCLC and invigorated research into immunotherapy in the field. In this review we consider the foundations of immunotherapy in NSCLC, canvass the current research and summarise the evidence guiding clinical practice.
引用
收藏
页数：14
相关论文
共 50 条
  • [1] Shifting Paradigms in Non-Small Cell Lung Cancer: An Evolving Therapeutic Landscape
    Riess, Jonathan
    [J]. AMERICAN JOURNAL OF MANAGED CARE, 2013, 19 (19): : S390 - S397
  • [2] Immunotherapy for Non-Small Cell Lung Cancer
    Yoon, Sung Ho
    [J]. TUBERCULOSIS AND RESPIRATORY DISEASES, 2014, 77 (03) : 111 - 115
  • [3] Immunotherapy for non-small cell lung cancer
    Vafadar, Sam
    [J]. JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS, 2019, 32 (09): : 37 - 42
  • [4] Immunotherapy in non-small cell lung cancer
    Peters, Geoffrey
    John, Thomas
    [J]. CANCER FORUM, 2018, 42 (01) : 24 - 28
  • [5] Immunotherapy for non-small cell lung cancer
    Kagamu, Hiroshi
    [J]. RESPIRATORY INVESTIGATION, 2024, 62 (02) : 307 - 312
  • [6] Prognostic models for immunotherapy in non-small cell lung cancer: A comprehensive review
    Ni, Siqi
    Liang, Qi
    Jiang, Xingyu
    Ge, Yinping
    Jiang, Yali
    Liu, Lingxiang
    [J]. HELIYON, 2024, 10 (08)
  • [7] Immunotherapy in metastatic non-small cell lung cancer: EPSILoN as a prognostic score
    Valente, M. C. Alves
    Serino, M.
    Freitas, C.
    Martins, M.
    Ferreira, P.
    Cardoso, C.
    Sousa, C.
    Santos, V.
    Araujo, D.
    Novais-Bastos, H.
    Magalhaes, A.
    Queiroga, H.
    Fernandes, G.
    Hespanhol, V.
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [8] Biomarkers of immunotherapy for non-small cell lung cancer
    Shirasawa, Masayuki
    Yoshida, Tatsuya
    Ohe, Yuichiro
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 54 (01) : 13 - 22
  • [9] Principles of Immunotherapy in Non-Small Cell Lung Cancer
    Hsu, Melinda L.
    Naidoo, Jarushka
    [J]. THORACIC SURGERY CLINICS, 2020, 30 (02) : 187 - +
  • [10] Perioperative Immunotherapy in Non-Small Cell Lung Cancer
    Jenny O’Brien
    J. Nicholas Bodor
    [J]. Current Treatment Options in Oncology, 2023, 24 : 1790 - 1801
12345